Drug profile · INN
methoxy polyethylene glycol-epoetin beta
MIRCERA
methoxy polyethylene glycol-epoetin beta (MIRCERA) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Drug details — methoxy polyethylene glycol-epoetin beta
- US status
- approved
- Class
- Blood and blood forming organs (B03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
methoxy polyethylene glycol-epoetin beta (MIRCERA) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methoxy polyethylene glycol-epoetin beta?
methoxy polyethylene glycol-epoetin beta (MIRCERA) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for methoxy polyethylene glycol-epoetin beta?
MIRCERA is a marketed brand name for methoxy polyethylene glycol-epoetin beta. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methoxy polyethylene glycol-epoetin beta?
methoxy polyethylene glycol-epoetin beta has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.